
Submission Guideline
1. The organizers of NBHC-2021 welcome all abstracts within the scope of the meeting. Submitted abstracts will
be reviewed by experts and be scheduled for either oral or poster presentation during the congress if the topic
is relevant and the quality of the data justifies scheduling. Irrelevant or poor-quality abstracts may be
rejected.
2. An Abstracts can be submitted online through the congress website. It is advisable to prepare the complete
text of your abstract as well as any figures/tables before accessing online abstract submission.
3. Abstracts need to written in clear English, taking into account the specifications below.
a. Maximum word count of abstract title: 20 words.
b. Maximum word count of abstract text: 350 words (adjust in case of tables/figures).
c. Abstract topic should be selected during the online submission process from the list of predefined topics to
facilitate abstract review and scheduling.
d. A minimum of three specific keywords should be added during online submission for indexing of the abstract.
Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied,
biochemical or biological function(s) studied. Avoid the use of vague keywords, such as: angiogenesis, cell
death, cancer, tumor, drug development, drug therapy. The Organizing Committee of NBHC-2021 reserves the
rights
to delete, edit, or add keywords to achieve uniformity throughout abstract publications.
e. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract.
Proprietary names may be used in the abstract text, not the abstract title. The first time the drug is mentioned
use the INN and put proprietary names between brackets.
f. The identity of a new, previously unpublished drug substance should be disclosed in the abstract, either by providing its structural formula or its full chemical name
4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However,
non-adherence to the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting
organizers.
5. After submission, abstracts can no longer be changed by the authors. Should minor changes be necessary after
submission, the author should notify Anna at anna-neurotalk@eventcomittee.com,
describing exactly the nature of the change to
be made. The NBHC-2021 organizers will then implement the change. If major changes are required the
author should
submit a revised abstract as an entirely new abstract and send a request to anna-neurotalk@eventcomittee.com
to delete the
original abstract. The addition of a co-author constitutes a major change.
6. After completion of the abstract review, the submitting author will receive scheduling information via email.
Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The
presenting author must be registered as a participant of NBHC-2021 for final scheduling and publication
of the
abstract.
7. Accepted abstracts will be published in the Conference Proceedings. The authors of the submitted abstracts
are responsible for any Intellectual Property issues concerning the abstracts on their own. The organizing
committee of NBHC-2021 reserves the right to use submitted abstracts for conference purposes.



International Alzheimer Industry Alliance
SHUANGDI•ZHEN-AOHEATH INDUSTRY GROUP
Goldstone Innovation Institute
Dr. Zang-Hee Cho,
Professor, Neuroscience Research Institute, The University of Suwon, South Korea
Dr. George R. Lee,
Past President, American Society of Neurophysiological Monitoring, USA
Dr. Guy R Seabrook,
Vice President & Global Lead, Neuroscience External Innovation, Janssen Research & Development, Johnson & Johnson Innovation, South San Francisco, USA
Dr. John Nicholas Pepys Rawlins,
Pro-Vice-Chancellor, the University of Oxford, UK; Professor, Chinese University of Hong Kong, Hong Kong, China
Dr. Jianguo Cheng,
President, American Academy of Pain Medicine; Professor and Director, Cleveland Clinic Multidisciplinary Pain Medicine FellowshipCleveland Clinic, USA
Dr. Yang D. Teng,
President, The American Society for Neural Therapy and Repair, USA
Dr. Niall T M Galloway,
Associate Professor, Emory University, USA
Dr. Francisco Fernandez Nistal,
CEO, Asociacion de Dano Cerebral de Navarra (ADACEN), Spain
Dr. Yukio Yoneda,
Professor Emeritus, Kanazawa University, Japan
Dr. Hsiao-Yuan Lee,
Distinguished Research Fellow, Institute of Biomedical Sciences, Academia Sinica, Taiwan
Dr. Jianwu Dang,
Professor, Japan Advanced Institute of Science and Technology, Japan
Dr. Florence Levy,
Head, Prince of Wales Hospital, Australia
Dr. April R Wiechmann,
Director, Neuropsychology Clinic, Associate Professor, University of North Texas Health Science Center, USA
Dr. Lakshmi D. Katikaneni,
Professor, Medical University of South Carolina, USA
Dr. Kwoon Y. Wong,
Associate Professor, University of Michigan, USA
Dr. Jozsef Zoltan Kiss,
Professor, University of Geneva Medical School, Switzerland
Dr. David R. Gater,
Professor, Penn State College of Medicine, USA
Dr. Yumin Zhang,
Associate Professor, Uniformed Services University, USA
Dr. Leo Petrossian,
CEO Neural Analytics, USA
Dr. Alberto de Bellis,
Founder & President, Maria Rosaria Maglione Foundation Onlus, Italy
Dr. Stefan Strotzka,
Professor, Geronto-Psychiatric Center for Psychosocial Services in Vienna, Austria
Dr. Fumisuke Matsuo,
Clinical Professor, University of Utah, USA
Dr. Andrew Worthington,
Director, Headwise, UK
Dr. Anna Cornelia Beyer,
Senior Lecturer, University of Hull, UK
Dr. Drew A. Nagele,
Clinical Professor, Philadelphia College of Osteopathic Medicine, USA
Dr. Chuk-ling Julian Lai,
Associate Professor, City University of Hong Kong, Hong Kong, China
Dr. Gabrielle Todd,
Associate Professor, University of South Australia, Australia
Dr. Weiya Ma,
Assistant Professor, University of McGill, Canada
Dr. Istvan J.E. Boksay,
Clinical Professor, New York University, USA
Dr. Shaobai Zhang,
Professor, Nanjing University of Posts and Telecommunications, China
Dr. Cai Song,
Professor, Director, Institute for Marine Drugs and Nutrition; Director, Marine Medicine Develop.Cent. Shenzhen Institute; Guangdong Ocean University, China
©2010-2021 All right reserved by BIT Congress Inc. Tel: +86-411-8479 9609-816, Fax: +86-411-8479 6897 |